Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Asio Capital LLC

Asio Capital LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,518 shares of the biopharmaceutical company’s stock after buying an additional 724 shares during the quarter. Asio Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $2,506,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $49,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $675.79 on Friday. The firm’s 50 day moving average is $727.19 and its two-hundred day moving average is $937.77. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $74.26 billion, a P/E ratio of 16.72, a P/E/G ratio of 1.59 and a beta of 0.10.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.